TITLE:
      A Trial for Patients With Gestational Trophoblastic Disease
SUMMARY:
      This phase II study is evaluating the activity of Pemetrexed in patients diagnosed with low
      risk Gestational Trophoblastic Tumor (GTT) that have failed prior treatment.
ELIGIBILITY CRITERIA:
      Inclusion Criteria:

          -  Persistent or recurrent low risk Gestational Trophoblastic Tumor (GTT)

          -  WHO score 2-6 (re-evaluated at the time of relapse

          -  Histologically confirmed complete or partial moles on initial evacuation

          -  Patients with mild to moderate renal insufficiency should avoid taking NSAIDs with
             short elimination half-lives for a period of 2 days before, the day of, and 2 days
             following administration of pemetrexed.

          -  All patients taking NSAIDs with longer half-lives, should interrupt dosing for at
             least 5 days before, the day of, and 2 days following pemetrexed administration.

          -  Folic Acid (350-1000 micrograms) must be given daily beginning approximately 5-7 days
             prior to first dose of pemetrexed and continuing daily until 3 weeks after the last
             dose of study therapy.

          -  Vitamin B12 (1000 micrograms) will be administered as an intramuscular injection
             approximately 1 to 2 weeks prior to first dose of pemetrexed and repeated
             approximately every 9 weeks until 3 weeks after the last dose of study therapy.

        Exclusion Criteria:

          -  Previous treatment that included chemotherapy other than actinomycin -D or
             methotrexate (+/- folinic acid).

          -  Patients with more than 8 metastatic lesions identified

          -  Patients with metastases to liver, spleen, brain, kidney or GI tract
